sb 203580 has been researched along with damnacanthal in 1 studies
Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (damnacanthal) | Trials (damnacanthal) | Recent Studies (post-2010) (damnacanthal) |
---|---|---|---|---|---|
3,489 | 4 | 1,137 | 55 | 0 | 30 |
Protein | Taxonomy | sb 203580 (IC50) | damnacanthal (IC50) |
---|---|---|---|
Tyrosine-protein kinase Lck | Homo sapiens (human) | 0.3185 | |
LIM domain kinase 1 | Homo sapiens (human) | 0.8 | |
LIM domain kinase 2 | Homo sapiens (human) | 1.53 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M | 1 |
1 other study(ies) available for sb 203580 and damnacanthal
Article | Year |
---|---|
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases | 2007 |